Overview

Long Term Use Of Xalacom In Patients Glaucoma Or Ocular Hypertension

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
0
Participant gender:
All
Summary
The objective of this Investigation is to evaluate the safety and efficacy of long-term treatment with Xalacom in medical practice. Also, occurrence of unknown and known adverse drug reactions (ADRs) in subjects treated with Xalacom will be monitored during the survey period, and whether an additional treatment outcome investigation and/or a post-marketing clinical study is required in the future will be determined.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Latanoprost
Maleic acid
Ophthalmic Solutions
Timolol
Criteria
Inclusion Criteria:

- Patients need to be administered Xalacom® in order to be enrolled in the surveillance.

Exclusion Criteria:

- Patients not administered Xalacom®.